WO2011045810A1 - Pharmaceutical compositions containing taurine and race-methionine for the treatment of alcoholism - Google Patents
Pharmaceutical compositions containing taurine and race-methionine for the treatment of alcoholism Download PDFInfo
- Publication number
- WO2011045810A1 WO2011045810A1 PCT/IN2010/000530 IN2010000530W WO2011045810A1 WO 2011045810 A1 WO2011045810 A1 WO 2011045810A1 IN 2010000530 W IN2010000530 W IN 2010000530W WO 2011045810 A1 WO2011045810 A1 WO 2011045810A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alcohol
- methionine
- taurine
- liver
- race
- Prior art date
Links
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 title claims abstract description 50
- 229960003080 taurine Drugs 0.000 title claims abstract description 23
- 208000007848 Alcoholism Diseases 0.000 title claims abstract description 16
- 201000007930 alcohol dependence Diseases 0.000 title claims abstract description 14
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 title claims abstract description 12
- 229940080308 racemethionine Drugs 0.000 title claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 33
- 210000004185 liver Anatomy 0.000 claims abstract description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 16
- 230000000694 effects Effects 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 4
- 229940067606 lecithin Drugs 0.000 claims abstract description 4
- 239000000787 lecithin Substances 0.000 claims abstract description 4
- 235000010445 lecithin Nutrition 0.000 claims abstract description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 6
- 229930182817 methionine Natural products 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 229910021529 ammonia Inorganic materials 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 206010005052 Bladder irritation Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 229910001385 heavy metal Inorganic materials 0.000 claims description 2
- 208000027753 pain disease Diseases 0.000 claims description 2
- 230000002503 metabolic effect Effects 0.000 abstract description 5
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 abstract description 4
- 230000003078 antioxidant effect Effects 0.000 abstract description 4
- 238000006243 chemical reaction Methods 0.000 abstract description 4
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 abstract description 4
- 239000002207 metabolite Substances 0.000 abstract description 3
- 235000019441 ethanol Nutrition 0.000 description 30
- 238000000034 method Methods 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 241000208125 Nicotiana Species 0.000 description 8
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 239000003925 fat Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 6
- 206010019708 Hepatic steatosis Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 229960004452 methionine Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 description 3
- 229960004047 acamprosate Drugs 0.000 description 3
- 230000002075 anti-alcohol Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- -1 oral irrigators Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- RCLLNBVPCJDIPX-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[2-(dimethylsulfamoyl)ethyl]-1-nitrosourea Chemical compound CN(C)S(=O)(=O)CCNC(=O)N(N=O)CCCl RCLLNBVPCJDIPX-UHFFFAOYSA-N 0.000 description 2
- NZKNHIQZWSVJGP-UHFFFAOYSA-N 2-(1,3-dioxoisoindol-2-yl)-n-propan-2-ylethanesulfonamide Chemical compound C1=CC=C2C(=O)N(CCS(=O)(=O)NC(C)C)C(=O)C2=C1 NZKNHIQZWSVJGP-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 208000003443 Unconsciousness Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 206010001584 alcohol abuse Diseases 0.000 description 2
- 208000025746 alcohol use disease Diseases 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 201000009032 substance abuse Diseases 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229950005780 taltrimide Drugs 0.000 description 2
- 229950010168 tauromustine Drugs 0.000 description 2
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 description 1
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- 201000010053 Alcoholic Cardiomyopathy Diseases 0.000 description 1
- 101000769652 Alnus glutinosa Acetylornithine aminotransferase, mitochondrial Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 101000769650 Arabidopsis thaliana Acetylornithine aminotransferase, chloroplastic/mitochondrial Proteins 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010071238 Binge Drinking Diseases 0.000 description 1
- 206010007637 Cardiomyopathy alcoholic Diseases 0.000 description 1
- 206010008027 Cerebellar atrophy Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010013142 Disinhibition Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010069350 Osmotic demyelination syndrome Diseases 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 240000003444 Paullinia cupana Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000010045 Wernicke encephalopathy Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 208000029650 alcohol withdrawal Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000003858 bile acid conjugate Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 208000009885 central pontine myelinolysis Diseases 0.000 description 1
- 201000004559 cerebral degeneration Diseases 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229940006423 chondroitin sulfate sodium Drugs 0.000 description 1
- 230000003011 chondroprotective effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229960001911 glucosamine hydrochloride Drugs 0.000 description 1
- 229960002849 glucosamine sulfate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 239000006049 herbal material Substances 0.000 description 1
- 229940089491 hydroxycitric acid Drugs 0.000 description 1
- 239000002117 illicit drug Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229940016409 methylsulfonylmethane Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000019505 tobacco product Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
Definitions
- compositions containing taurine and race-methionine for the treatment of alcoholism are provided.
- the invention relates generally to pharmaceutical composition containing taurine and race-methionine for the treatment of alcoholism.
- a nutritional product for cancer patients comprising, as per caloric requirement, a low concentration of carbohydrate, a high concentration of fat and an imbalance of amino acids wherein L-phenylalanine, L-tyrosine and L-methionine are present in the below normal concentrations and L-leucine is present in substantial excess of normal concentrations to suppress cancer growth and as an adjunct to conventional cancer therapies
- compositions and methods of administration are designed to effectively elevate and sustain blood levels of said compounds in turn enhancing the body's natural chondroprotective mechanisms while providing an efficient delivery mechanism which optimizes cellular uptake of glucosamine and chondroitin.
- This process of forming specified synergistic relationships between vital metabolic precursors increases the body's production of proteoglycans, chondrocytes, hyalauron glycosaminoglycans and collagen, facilitating the repair and regeneration of articular cartilage and symptomatic relief from pain and inflammation associated with articular degeneration.
- the present invention relates to a health supplement food utilizing, in particular, branched amino acids from among essential amino acids. More specifically, the present invention relates to: a health supplement food comprising branched chain amino acids (hereinafter, referred to as LIV) composed of leucine (L), isoleucine (I) and valine (V) which is made to have a composition similar to essential amino acids contained in naturally-occurring milk, eggs, soybeans, beef and the like, and enhancing instant impact power under anaerobic conditions, via addition of L- glutamine and taurine which are essentially required when a person is exposed to excessive exercise, stress or overwork; a health supplement food for improving a weak constitution, comprising herbal materials such as ginseng, red ginseng and Acanthopanax; and a diet food or beverage further comprising dietary fibers such as inulin, polydextrose and crystalline cellulose, and carnitine and hydroxy citric acid.
- LIV branched chain amino acids
- LIV branched
- An exemplary dried, meat- based product includes meat and plant seed where the plant seed comprises at least approximately 3% caffeine by weight.
- an exemplary product includes guarana plant seed.
- plant seed may be provided as a powder
- compositions comprising one or more ionic salts, each of said ionic salts consisting of a bicarbonate anion and a cation selected from the group consisting of an amino acid, an amino acid derivative, a di- peptide and a tri-peptide, and to methods of making and using said compositions.
- the present invention is basically based on treatment of alcoholism by pharmaceutical composition.
- Alcoholism is a disease. It is often diagnosed more through behaviors and adverse effects on functioning than by specific medical symptoms. Alcoholics, when confronted, will often deny excess consumption of alcohol. Alcoholism is a diverse disease and is often influenced by the alcoholic's personality as well as by oilier factors. Therefore, signs and symptoms often vary from person to person. There are, however, certain behaviors and signs that indicate someone may have a problem with alcohol.
- Late signs and symptoms include medical conditions such as pancreatitis, gastritis, cirrhosis, neuropathy, anemia, cerebellar atrophy, alcoholic cardiomyopathy (heart disease), Wernicke's encephalopathy (abnormal brain functioning), Korsakoff s dementia, central pontine myelinolysis (brain degeneration), seizures, confusion, malnutrition, hallucinations, peptic ulcers, and gastrointestinal bleeding.
- EFFECT OF ALCOHOLISM IN LIVER- Alcohol abuse can cause a condition called "fatty liver” or another called “alcohol hepatitis”— both of which can be treated, but only if alcohol consumption is stopped. If drinking continues, these conditions will cause cirrhosis of the liver. Alcoholism is called a progressive disease, meaning that over time the symptoms and effects of drinking alcohol become more intense and severe. The symptoms in the early stages differ from those during later stages as the disease progresses from binge drinking to alcohol abuse to alcohol dependence.
- the liver detoxifies poisons, both those produced by the body and those from outside; filters bacteria from the blood; regulates fat metabolism; stores and manufactures vitamins; regulates and manufactures cholesterol and fats; synthesizes proteins; maintains the body's water and salt balance; secretes bile for the digestion of fat; stores energy (in the form of glycogen) helps regulate overall body metabolism; transforms the highly toxic ammonia (produced by exercise and by metabolism of proteins) into urea which is eliminated in the urine; manufactures lipoproteins for fat and cholesterol transport; and metabolizes alcohol.
- Information dissemination This strategy provides awareness and knowledge of the nature and extent of alcohol, tobacco, and other drug use, abuse, and addiction and their effects on individuals, families, and communities, as well as information to increase perceptions of risk. It also provides knowledge and awareness of prevention policies, programs, and services. It helps set and reinforce norms (for example, underage drinking and drug dealers will not be tolerated in this neighborhood).
- Prevention education This strategy aims to affect critical life and social skills, including decision making, refusal skills, critical analysis (for example, of media messages), and systematic and judgmental abilities.
- This strategy aims to enhance the ability of the community to provide prevention and treatment services to alcohol, tobacco, and other drug use disorders more effectively. Activities include organizing, planning, enhancing efficiency and effectiveness of services implementation, interagency collaboration, coalition building, and networking. Building healthy communities encourages healthy lifestyle choices. Environmental approach. This strategy sets up or changes written and unwritten community standards, codes, and attitudes— influencing incidence and prevalence of alcohol, tobacco, and other drug use problems in the general population. Included are laws to restrict availability and access, price increases, and community-wide actions.
- the main object of the invention is to provide the composition of pharmaceutical which is comparatively more effective than others as it contains taurine and race- methionin.
- Taurine or 2-aminoethanesulfonic acid, is an organic acid. Taurine can either promote or repress the reward effects associated with alcohol; the delineating factor being the amount of alcohol consumed its role in alcoholism. Its major metabolite taurocholic acid is responsible for the metabolic conversion of alcohol. Race Methionine has antioxidant properties. It prevents lower cholesterol levels by increasing the liver's production of lecithin, reduces liver fat and protects the kidneys.
- This invention is based on a pharmaceutical composition containing taurine and race-methionine for treating alcoholism. Both are helpful for protection to liver by alcohol.
- the liver is the largest glandular organ of the body.
- the liver has many functions. Some of the functions are: to produce substances that break down fats, convert glucose to glycogen, produce urea (the main substance of urine), make certain amino acids (the building blocks of proteins), filter harmful substances from the blood (such as alcohol), storage of vitamins and minerals (vitamins A, D, K and Bl 2) and maintain a proper level or glucose in the blood.
- the liver is also responsible for producing cholesterol. It produces about 80% of the cholesterol in your body.
- the main disease of liver is Alcohol alters the metabolism of the liver, which can have overall detrimental effects if alcohol is taken over long periods of time
- alcohol can cause:
- Taurine or 2-aminoethanesulfonic acid- It is an organic acid. Taurine is one of the most abundant amino acids in the body . It is also a major constituent of bile and can be found in the lower intestine and in small amounts in the tissues of many animals, including humans. Taurine is a derivative of the sulfur-containing (sulfhydryl) amino acid, cysteine. Taurine is one of the few known naturally occurring sulfonic acids. It has a number of roles regarding normal functioning of the brain, heart, gallbladder, eyes and vascular system. It functions to facilitate the movement of mineral and salt ions in and out of the cells and to stabilize cell membranes.
- Ca N- acetylhomotaurinate (Ca AOTA) appears to be the most active anti-acetaldehyde and anti-alcohol agent.
- Large numbers of 1 taurine derivatives have been reported in the literature with partial to marked activity.
- Taurine derivatives like taltrimide, acamprosate and tauromustine are already in the market as anti-convulsant, anti-alcoholic and anti-cancer agents.
- Taurine derivatives like taltrimide, acamprosate and tauromustine are already in the market as anti-convulsant, anti-alcoholic and anticancer agents.
- Taurine can either promote or repress the reward effects associated with alcohol, the delineating factor being the amount of alcohol consumed. Its major metabolite taurocholic acid is responsible for the metabolic conversion of alcohol.
- the correlation of taurine with alcohol consumption scientists synthesized the drug acamprosate, the calcium salt of N-acetyl-homotaurinate. It is the first agent specifically designed to maintain abstinence in alcohol-dependent patients who have completed detoxification. It interacts with glutamanergic neurotransmission channels (NMDA receptors) to reduce calcium flux., resulting in a depressed interest in alcohol consumption.Acomprosate decreases glutamate elevations that are characteristic of alcohol withdrawal.
- NMDA receptors glutamanergic neurotransmission channels
- Hepatic steatosis 'fatty liver'
- lipid peroxidation by administering alcohol .
- hepatic steatosis was greatly reduced and lipid per oxidation completely prevented.
- Fatty liver was prevented in animals receiving taurine supplementation.
- the protective effect of taurine was attributed to the potential of taurine conjugated bile acids (particularly taurocholic acid) to inhibit adverse enzymatic functions associated with alcohol consumption. This elucidates the very crucial tasks that taurine performs to protect against the deleterious effects of chronic alcohol consumption.
- Methionine is one of the three amino acids needed by the body to manufacture Creatine, an amino acid essential for energy production and muscle building
- Methionine is a natural chelating agent for heavy metals. It regulates the formation of ammonia and creates ammonia-free urine, which reduces bladder irritation.
- Methionine is used in the liver as a detoxifying agent. It has also been used to treat depression, arthritis pain and chronic liver disease. Procedure of Manufacturing
Abstract
The present invention relates to Pharmaceutical compositions for the treatment of alcoholism which is containing taurine and race-methionine. Taurine can either promote or repress the reward effects associated with alcohol; the delineating factor being the amount of alcohol consumed, its role in alcoholism. Its major metabolite taurocholic acid is responsible for the metabolic conversion of alcohol. Race Methionine has antioxidant properties. It prevents lower cholesterol levels by increasing the liver's production of lecithin, reduces liver fat.
Description
Title of Invention:
Pharmaceutical compositions containing taurine and race-methionine for the treatment of alcoholism
FIELD OF THE INVENTION:
The invention relates generally to pharmaceutical composition containing taurine and race-methionine for the treatment of alcoholism.
PRIOR ART:
In existing method as given in, US Patent 5906811 wherein said The combination of several synergistic antioxidants, enzymatic co-factors and amino acids in appropriate delivery vehicles employed in aerosol carriers, mist and pump oral sprays, solutions, such as oral irrigators, mouth rinses and mouthwashes, or gels and solid compositions as a means of preventing and ameliorating signs and symptoms and complications to the oro-pharyngeal cavity and mouth including buccal mucosa, gums and tongue and the upper respiratory tract from damage caused by free radical species induced by tobacco smoke, smokeless tobacco, ingested or chewed noxious, malodorous or harmful substances and other inhaled environmental pollutants and particulate matter, including tobacco to secondary smokers.
In another existing method as given in United States Patent 5817695 wherein said A nutritional product is provided for cancer patients comprising, as per caloric requirement, a low concentration of carbohydrate, a high concentration of fat and an imbalance of amino acids wherein L-phenylalanine, L-tyrosine and L-methionine are present in the below normal concentrations and L-leucine is present in substantial excess of normal concentrations to suppress cancer growth and as an adjunct to conventional cancer therapies
In another existing method as given in European Patent EP1408988wherein said Provided is a synergistic combination of nutritional supplements classified as Nutraceuticals and further combined with antioxidant vitamins and minerals that, when orally administered to mammals, provides optimal delivery of vital metabolic precursors necessary for the production and repair of articular cartilage. Specifically provided is, a unique combination of chondroitin sulfate sodium, methylsulfonylmethane, glucosamine potassium, glucosamine hydrochloride, glucosamine sulfate sodium, N-acetyl D- Glucosamine, sodium absorbate and chelated manganese proteinate compounded through agitation. The provided compositions and methods of administration are designed to effectively elevate and sustain blood levels of said compounds in turn enhancing the body's natural chondroprotective mechanisms while providing an efficient delivery mechanism which optimizes cellular uptake of glucosamine and chondroitin. This process of forming specified synergistic relationships between vital metabolic precursors increases the body's production of proteoglycans, chondrocytes, hyalauron glycosaminoglycans and collagen, facilitating the repair and regeneration of articular cartilage and symptomatic relief from pain and inflammation associated with articular degeneration.
In another existing method as given inWO 2006/062273 Al, wherein said The present invention relates to a health supplement food utilizing, in particular, branched amino acids from among essential amino acids. More specifically, the present invention relates to: a health supplement food comprising branched chain amino acids (hereinafter, referred to as LIV) composed of leucine (L), isoleucine (I) and valine (V) which is made to have a composition similar to essential amino acids contained in naturally-occurring milk, eggs, soybeans, beef and the like, and enhancing instant impact power under anaerobic conditions, via addition of L- glutamine and taurine which are essentially required when a person is exposed to excessive exercise, stress or overwork; a health supplement food for improving a weak constitution, comprising herbal materials such as ginseng, red ginseng and Acanthopanax; and a diet food or beverage further comprising dietary fibers such as inulin, polydextrose and crystalline cellulose, and carnitine and hydroxy citric acid.
In another existing method as given in WO 2007/115112 A2wherein said An exemplary dried, meat- based product includes meat and plant seed where the plant seed comprises at least approximately 3% caffeine by weight. For example, an exemplary product includes guarana plant seed. According to various products and processes, plant seed may be provided as a powder
In another existing method as given in US 2009/0005320 Al wherein said The invention relates to compositions comprising one or more ionic salts, each of said ionic salts consisting of a bicarbonate anion and a cation selected from the group consisting of an amino acid, an amino acid derivative, a di- peptide and a tri-peptide, and to methods of making and using said compositions.
BACKGROUND OF INVENTION: The present invention is basically based on treatment of alcoholism by pharmaceutical composition. Alcoholism is a disease. It is often diagnosed more through behaviors and adverse effects on functioning than by specific medical symptoms. Alcoholics, when confronted, will often deny excess consumption of alcohol. Alcoholism is a diverse disease and is often influenced by the alcoholic's personality as well as by oilier factors. Therefore, signs and symptoms often vary from person to person. There are, however, certain behaviors and signs that indicate someone may have a problem with alcohol. These behaviors and signs include insomnia, frequent falls, bruises of different ages, blackouts, chronic depression, anxiety, irritability, tardiness or absence at work or school, loss of employment, divorce or separation, financial difficulties, frequent intoxicated appearance or behavior, weight loss, or frequent automobile collisions. Late signs and symptoms include medical conditions such as pancreatitis, gastritis, cirrhosis, neuropathy, anemia, cerebellar atrophy, alcoholic cardiomyopathy (heart disease), Wernicke's encephalopathy (abnormal brain functioning), Korsakoff s dementia, central pontine myelinolysis (brain degeneration), seizures, confusion, malnutrition, hallucinations, peptic ulcers, and gastrointestinal bleeding.
EFFECT OF ALCOHOLISM IN LIVER- Alcohol abuse can cause a condition called "fatty liver" or another called "alcohol hepatitis"— both of which can be treated, but only if alcohol consumption is stopped. If drinking continues, these conditions will cause cirrhosis of the liver. Alcoholism is called a progressive disease, meaning that over time the symptoms and effects of drinking alcohol become more intense and severe. The symptoms in the early stages differ from those during later stages as the disease progresses from binge drinking to alcohol abuse to alcohol dependence. The liver detoxifies poisons, both those produced by the body and those from outside; filters bacteria from the blood; regulates fat metabolism; stores and manufactures vitamins; regulates and manufactures cholesterol and fats; synthesizes proteins; maintains the body's water and salt balance; secretes bile for the digestion of fat; stores energy (in the form of glycogen) helps regulate overall body metabolism; transforms the highly toxic ammonia (produced by exercise and by metabolism of proteins) into urea
which is eliminated in the urine; manufactures lipoproteins for fat and cholesterol transport; and metabolizes alcohol.
If the liver stops doing any of these jobs, or numerous others it does constantly, the result is fatal. Self Care
Information dissemination. This strategy provides awareness and knowledge of the nature and extent of alcohol, tobacco, and other drug use, abuse, and addiction and their effects on individuals, families, and communities, as well as information to increase perceptions of risk. It also provides knowledge and awareness of prevention policies, programs, and services. It helps set and reinforce norms (for example, underage drinking and drug dealers will not be tolerated in this neighborhood).
Prevention education. This strategy aims to affect critical life and social skills, including decision making, refusal skills, critical analysis (for example, of media messages), and systematic and judgmental abilities.
Alternatives^ This strategy provides for the participation of targeted populations in activities that exclude alcohol, tobacco, and other drag use by youth. Constructive and healthy activities offset the attraction to, or otherwise meet the needs usually filled by, alcohol, tobacco, and other drug use.
Problem identification and referral. This strategy calls for identification, education, and counseling for tnose youth who have indulged in age-inappropriate use of tobacco products or alcohol, or who have indulged in the first use of illicit drugs. Activities under this strategy would include screening for tendencies toward substance abuse and referral for preventive treatment for curbing such tendencies.
Community-based process. This strategy aims to enhance the ability of the community to provide prevention and treatment services to alcohol, tobacco, and other drug use disorders more effectively. Activities include organizing, planning, enhancing efficiency and effectiveness of services implementation, interagency collaboration, coalition building, and networking. Building healthy communities encourages healthy lifestyle choices.
Environmental approach. This strategy sets up or changes written and unwritten community standards, codes, and attitudes— influencing incidence and prevalence of alcohol, tobacco, and other drug use problems in the general population. Included are laws to restrict availability and access, price increases, and community-wide actions.
OBJECT OF THE INVENTION: The main object of the invention is to provide the composition of pharmaceutical which is comparatively more effective than others as it contains taurine and race- methionin. Taurine, or 2-aminoethanesulfonic acid, is an organic acid. Taurine can either promote or repress the reward effects associated with alcohol; the delineating factor being the amount of alcohol consumed its role in alcoholism. Its major metabolite taurocholic acid is responsible for the metabolic conversion of alcohol. Race Methionine has antioxidant properties. It prevents lower cholesterol levels by increasing the liver's production of lecithin, reduces liver fat and protects the kidneys.
STATEMENT OF THE INVENTION: This invention is based on a pharmaceutical composition containing taurine and race-methionine for treating alcoholism. Both are helpful for protection to liver by alcohol.
DETAILED DESCRIPTION OF INVENTION: The liver is the largest glandular organ of the body. The liver has many functions. Some of the functions are: to produce substances that break down fats, convert glucose to glycogen, produce urea (the main substance of urine), make certain amino acids (the building blocks of proteins), filter harmful substances from the blood (such as alcohol), storage of vitamins and minerals (vitamins A, D, K and Bl 2) and maintain a proper level or glucose in the blood. The liver is also responsible for producing cholesterol. It produces about 80% of the cholesterol in your body. The main disease of liver is Alcohol alters the metabolism of the liver, which can have overall detrimental effects if alcohol is taken over long periods of time
Short-term effects
Depending on how much you drink, your experience with alcohol and the environment in which you are drinking, alcohol can cause:
• relaxation, feeling of well-being
• loss of inhibitions
• dizziness, unclear judgement
• uncoordinated movements, slow reactions
• blurred vision, slurred speech
• unconsciousness
• death
Taurine or 2-aminoethanesulfonic acid- It is an organic acid. Taurine is one of the most abundant amino acids in the body . It is also a major constituent of bile and can be found in the lower intestine and in small amounts in the tissues of many animals, including humans. Taurine is a derivative of the sulfur-containing (sulfhydryl) amino acid, cysteine. Taurine is one of the few known naturally occurring sulfonic acids. It has a number of roles regarding normal functioning of the brain, heart, gallbladder, eyes and vascular system. It functions to facilitate the movement of mineral and salt ions in and out of the cells and to stabilize cell membranes. Among several taurine derivatives, Ca N- acetylhomotaurinate (Ca AOTA) appears to be the most active anti-acetaldehyde and anti-alcohol agent. Large numbers of 1 taurine derivatives have been reported in the literature with partial to marked activity. Taurine derivatives like taltrimide, acamprosate and tauromustine, are already in the market as anti-convulsant, anti-alcoholic and anti-cancer agents. Taurine derivatives like taltrimide, acamprosate and tauromustine, are already in the market as anti-convulsant, anti-alcoholic and anticancer agents.
MECHANISM OF TAURJ NE -
Taurine can either promote or repress the reward effects associated with alcohol, the delineating factor being the amount of alcohol consumed. Its major metabolite taurocholic acid is responsible for the metabolic conversion of alcohol. The correlation of taurine with alcohol consumption, scientists synthesized the drug acamprosate, the calcium salt of N-acetyl-homotaurinate. It is the first agent specifically designed to maintain abstinence in alcohol-dependent patients who have completed detoxification. It interacts with glutamanergic neurotransmission channels (NMDA receptors) to reduce calcium flux., resulting in a depressed interest in alcohol consumption.Acomprosate decreases glutamate elevations that are characteristic of alcohol withdrawal. It's also use for Hepatic steatosis ('fatty liver') and lipid peroxidation by administering alcohol .hepatic steatosis was greatly reduced and lipid per oxidation completely prevented. Fatty liver was prevented in animals receiving taurine supplementation. The protective effect of taurine was attributed to the potential of taurine conjugated bile acids (particularly taurocholic acid) to inhibit adverse enzymatic functions associated with alcohol consumption. This elucidates the very crucial tasks that taurine performs to protect against the deleterious effects of chronic alcohol consumption.
RACE- METHIONINE (Essential)
L-Metbionine has antioxidant properties. Methionine is one of the three amino acids needed by the body to manufacture Creatine, an amino acid essential for energy production and muscle building
MECHANISM OF RACE-METHIONINE
It prevents disorders of the hair, skin and nails, helps lower cholesterol levels by increasing the liver's production of lecithin, reduces liver fat and protects the kidneys. Methionine is a natural chelating agent for heavy metals. It regulates the formation of ammonia and creates ammonia-free urine, which reduces bladder irritation.
Methionine is used in the liver as a detoxifying agent. It has also been used to treat depression, arthritis pain and chronic liver disease.
Procedure of Manufacturing
. QUANTITATIVE FORMULA:
PART IV: COATING
LIST OF EQUIPMENTS / MACHINES TO BE USED FOR MANUFACTURING
SR. NAME OF EQUIPMENT / MACHINE
NO.
1 Sifter
2 Octagonal Blender
3 Planetary Mixer [ 100 Lits. ]
4 Fluid Bed Dryer capacity 60 Kg. with SS Trolleys / Tray Dryer
5 Multi-mill
6 Tablet compression machine
7 Stainless steel scoops
8 Infrared moisture balance
9 Digital balance capacity 150 Kg. & 5 Kg.
10 D.T Apparatus
11 Hardness Tester
12 Friability Test Apparatus '
13 Micrometer / Vernier
14 Plastic. Inprocess containers
15 Stirrer
• MANUFACTURING PROCESS:
Claims
( 1 ) Pharmaceutical compositions for the treatment of alcoholism which is containing taurine and race- methionine wherein said Taurine can either promote or repress the reward effects associated with alcohol, the delineating factor being the amount of alcohol consumed.
(2) The Pharmaceutical composition as recited in Claim 1 wherein said race methionine prevents disorders of the hair, skin and nails, helps lower cholesterol levels by increasing the liver's production of lecithin, reduces liver fat.
(3) The Pharmaceutical composition as recited in Claims 1 & 2 wherein said methionine is a natural chelating agent for heavy metals. It regulates the formation of ammonia and creates ammonia-free urine, which reduces bladder irritation.
(4) The Pharmaceutical composition as recited in Claims 1, 2 & 3 wherein said methionine is used in the liver as a detoxifying agent. It has also been used to treat depression, arthritis pain and chronic liver disease.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1868MU2009 | 2009-08-13 | ||
| IN1868/MUM/2009 | 2009-08-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2011045810A1 true WO2011045810A1 (en) | 2011-04-21 |
| WO2011045810A4 WO2011045810A4 (en) | 2011-07-28 |
Family
ID=43719467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2010/000530 WO2011045810A1 (en) | 2009-08-13 | 2010-08-10 | Pharmaceutical compositions containing taurine and race-methionine for the treatment of alcoholism |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2011045810A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013124860A1 (en) * | 2012-02-23 | 2013-08-29 | Zota Health Care Ltd | Potent revital formulation |
| WO2015177805A1 (en) * | 2014-05-19 | 2015-11-26 | Zota Health Care Ltd | Combination of taurine and racemethionine for treatment of liver diseases |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5817695A (en) | 1997-12-24 | 1998-10-06 | Pellico; Michael A. | Nutritional product with high fat, low carbohydrate and amino acid imbalance |
| US5906811A (en) | 1997-06-27 | 1999-05-25 | Thione International, Inc. | Intra-oral antioxidant preparations |
| US6451341B1 (en) * | 1990-02-05 | 2002-09-17 | Thomas J. Slaga | Time release formulation of vitamins, minerals and other beneficial supplements |
| EP1408988A1 (en) | 1999-11-02 | 2004-04-21 | Shawn Paul Madere | Compositions of orally administered nutritional supplements to repair articular cartilage |
| WO2006062273A1 (en) | 2004-12-10 | 2006-06-15 | Se-Gyu Kim | Branched-amino acid supplement food |
| US20070202215A1 (en) * | 2006-02-28 | 2007-08-30 | Zahramehran Salari Lak | Dietary nutritional supplements for persons consuming alcohol products |
| WO2007115112A2 (en) | 2006-03-29 | 2007-10-11 | Brian Levin | Dried meat products including at least one stimulant |
| WO2007114945A2 (en) * | 2006-04-04 | 2007-10-11 | Hill's Pet Nutrition, Inc. | Compositions and methods for enhancing the antioxidant status of animals |
| US20090005320A1 (en) | 2008-09-02 | 2009-01-01 | Bruce Kneller | Compositions comprising amino acid bicarbonate and methods of use thereof |
-
2010
- 2010-08-10 WO PCT/IN2010/000530 patent/WO2011045810A1/en active Application Filing
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6451341B1 (en) * | 1990-02-05 | 2002-09-17 | Thomas J. Slaga | Time release formulation of vitamins, minerals and other beneficial supplements |
| US5906811A (en) | 1997-06-27 | 1999-05-25 | Thione International, Inc. | Intra-oral antioxidant preparations |
| US5817695A (en) | 1997-12-24 | 1998-10-06 | Pellico; Michael A. | Nutritional product with high fat, low carbohydrate and amino acid imbalance |
| EP1408988A1 (en) | 1999-11-02 | 2004-04-21 | Shawn Paul Madere | Compositions of orally administered nutritional supplements to repair articular cartilage |
| WO2006062273A1 (en) | 2004-12-10 | 2006-06-15 | Se-Gyu Kim | Branched-amino acid supplement food |
| US20070202215A1 (en) * | 2006-02-28 | 2007-08-30 | Zahramehran Salari Lak | Dietary nutritional supplements for persons consuming alcohol products |
| WO2007115112A2 (en) | 2006-03-29 | 2007-10-11 | Brian Levin | Dried meat products including at least one stimulant |
| WO2007114945A2 (en) * | 2006-04-04 | 2007-10-11 | Hill's Pet Nutrition, Inc. | Compositions and methods for enhancing the antioxidant status of animals |
| US20090005320A1 (en) | 2008-09-02 | 2009-01-01 | Bruce Kneller | Compositions comprising amino acid bicarbonate and methods of use thereof |
Non-Patent Citations (8)
| Title |
|---|
| ALCOHOLISM, CLINICAL AND EXPERIMENTAL RESEARCH APR 1989 LNKD- PUBMED:2658650, vol. 13, no. 2, April 1989 (1989-04-01), pages 164 - 171, ISSN: 0145-6008 * |
| DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; April 1989 (1989-04-01), TABAKOFF B ET AL: "Methionine lowers circulating levels of acetaldehyde after ethanol ingestion.", XP002629096, Database accession no. NLM2658650 * |
| GUPTA ET AL: "Taurine analogues; a new class of therapeutics : retrospect and prospects", CURRENT MEDICINAL CHEMISTRY,, vol. 12, 1 January 2005 (2005-01-01), pages 2021 - 2039, XP002534926, DOI: DOI:10.2174/0929867054546582 * |
| KERAI M D ET AL: "Reversal of ethanol-induced hepatic steatosis and lipid peroxidation by taurine: a study in rats.", ALCOHOL AND ALCOHOLISM (OXFORD, OXFORDSHIRE) 1999 JUL-AUG LNKD- PUBMED:10456581, vol. 34, no. 4, July 1999 (1999-07-01), pages 529 - 541, XP002629095, ISSN: 0735-0414 * |
| LIEBER C S: "Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis", ALCOHOL, PERGAMON PRESS, LONDON, GB, vol. 34, no. 1, 1 August 2004 (2004-08-01), pages 9 - 19, XP004721099, ISSN: 0741-8329, DOI: DOI:10.1016/J.ALCOHOL.2004.07.008 * |
| LIEBER C S: "Liver diseases by alcohol and hepatitis C: Early detection and new insights in pathogenesis lead to improved treatment", AMERICAN JOURNAL ON ADDICTIONS 2001 US LNKD- DOI:10.1080/10550490150504128, vol. 10, no. SUPPL., 2001, pages 29 - 50, XP002629097, ISSN: 1055-0496 * |
| MASON B J ET AL: "Acamprosate for the treatment of alcohol dependence: a review of double-blind, placebo-controlled trials.", CNS SPECTRUMS FEB 2000 LNKD- PUBMED:18296999, vol. 5, no. 2, February 2000 (2000-02-01), pages 58 - 69, XP009146122, ISSN: 1092-8529 * |
| WU GAOFENG ET AL: "Effect of taurine on alcoholic liver disease in rats.", AMINO ACIDS MAR 2009 LNKD- PUBMED:18509591, vol. 36, no. 3, March 2009 (2009-03-01), pages 457 - 464, XP002629094, ISSN: 1438-2199 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013124860A1 (en) * | 2012-02-23 | 2013-08-29 | Zota Health Care Ltd | Potent revital formulation |
| WO2015177805A1 (en) * | 2014-05-19 | 2015-11-26 | Zota Health Care Ltd | Combination of taurine and racemethionine for treatment of liver diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011045810A4 (en) | 2011-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8329227B2 (en) | Compositions for improving mental performance | |
| US9504713B2 (en) | Anti-glycation methods and compositions | |
| US5597585A (en) | Vitamin/mineral composition | |
| Kato-Kataoka et al. | Soybean-derived phosphatidylserine improves memory function of the elderly Japanese subjects with memory complaints | |
| Patel et al. | Safety assessment of pomegranate fruit extract: acute and subchronic toxicity studies | |
| US5626849A (en) | Weight loss composition for burning and reducing synthesis of fats | |
| Ofoedu et al. | Revisiting food-sourced vitamins for consumer diet and health needs: a perspective review, from vitamin classification, metabolic functions, absorption, utilization, to balancing nutritional requirements | |
| EP2683373B1 (en) | Orthomolecular agent for countering the consequences of alcohol consumption | |
| RU2658380C1 (en) | Beverage for improvement of skin and joint condition | |
| WO2019053580A1 (en) | Energy drink composition | |
| US20130101569A1 (en) | Hair growth stimulant | |
| Hemat | Principles of orthomolecularism | |
| EP1469746A2 (en) | Modular system of dietary supplement compositions comprising vitamins | |
| AT513274A4 (en) | Dietary supplements | |
| WO2011045810A1 (en) | Pharmaceutical compositions containing taurine and race-methionine for the treatment of alcoholism | |
| GB2585619A (en) | A supplement | |
| EP3503745B1 (en) | Dietary macro/micronutritional supplement for patients undergoing kidney dialysis | |
| US20030194453A1 (en) | Dietary supplement | |
| DE10158498A1 (en) | Nutritional formulation, used to improve resistance to loss of motivation or concentration and infection, comprises the amino acids carnitine, glutamine, methionine, arginine and ornithine and the tripeptide glutathione | |
| Jodh et al. | An Updated Review on Vitamin C-An Excellent Drug Having a Great Scavenging Property | |
| KR20120110955A (en) | A functional beverage composition comprising taurine, inositol, vitamin c, vitamin b complex, potassium iodide as main ingredients | |
| US10485783B1 (en) | Methods and compositions for reducing or eliminating symptoms of withdrawal from drugs and alcohol | |
| Górska et al. | The Effects of the Action of Chromium, Aluminum, Nickel and Iron on Human Fibroblast and Stem Cell Cultures | |
| WO2007112963A1 (en) | Novel use of ascorbigen | |
| Ley | MSM: On Our Way Back To Health With Sulfur |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10782723 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 10782723 Country of ref document: EP Kind code of ref document: A1 |